|
MXPA03010129A
(es)
*
|
2001-05-05 |
2004-03-10 |
Smithkline Beecham Plc |
N-aroilaminas-ciclicas.
|
|
GB0115862D0
(en)
*
|
2001-06-28 |
2001-08-22 |
Smithkline Beecham Plc |
Compounds
|
|
GB0124463D0
(en)
*
|
2001-10-11 |
2001-12-05 |
Smithkline Beecham Plc |
Compounds
|
|
GB0127145D0
(en)
|
2001-11-10 |
2002-01-02 |
Smithkline Beecham |
Compounds
|
|
GB0130335D0
(en)
*
|
2001-12-19 |
2002-02-06 |
Smithkline Beecham Plc |
Compounds
|
|
CN1556705B
(zh)
|
2002-07-09 |
2010-04-28 |
埃科特莱茵药品有限公司 |
7,8,9,10-四氢-6H-氮杂卓并、6,7,8,9-四氢-吡啶并和2,3-二氢-2H-吡咯并[2,1-b]-喹唑啉酮衍生物
|
|
WO2004026866A1
(en)
*
|
2002-09-18 |
2004-04-01 |
Glaxo Group Limited |
N-aroyl cyclic amines as orexin receptor antagonists
|
|
RU2334735C2
(ru)
|
2002-10-11 |
2008-09-27 |
Актелион Фармасьютиклз Лтд. |
Производные сульфониламиноуксусной кислоты и их применение в качестве антагонистов рецепторов орексина
|
|
GB0225944D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Glaxo Group Ltd |
Novel compounds
|
|
GB0225938D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Glaxo Group Ltd |
Novel compounds
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
JP2007523846A
(ja)
|
2003-04-28 |
2007-08-23 |
アクテリオン ファマシューティカルズ リミテッド |
キノキサリノン誘導体
|
|
PT1751111E
(pt)
|
2004-03-01 |
2015-04-01 |
Actelion Pharmaceuticals Ltd |
Derivados de 1,2,3,4-tetrahidroisoquinolina substituída
|
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
|
US20060178307A1
(en)
*
|
2005-01-26 |
2006-08-10 |
The Regents Of The University Of California |
Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor
|
|
US7501395B2
(en)
|
2005-04-25 |
2009-03-10 |
Eisai R & D Management Co., Ltd. |
Method of screening for antianxiety drugs
|
|
WO2006126074A2
(en)
*
|
2005-05-26 |
2006-11-30 |
Orchid Research Laboratories Limited |
Heterocyclic derivatives
|
|
WO2007136790A2
(en)
*
|
2006-05-18 |
2007-11-29 |
Mannkind Corporation |
Intracellular kinase inhibitors
|
|
JP2009543785A
(ja)
|
2006-07-14 |
2009-12-10 |
メルク エンド カムパニー インコーポレーテッド |
架橋ジアゼパンオレキシン受容体アンタゴニスト
|
|
US20100016401A1
(en)
*
|
2006-09-29 |
2010-01-21 |
Actelion Phamaceuticals Ltd. |
3-aza-bicyclo[3.1.0]hexane derivatives
|
|
ES2357992T3
(es)
|
2006-12-01 |
2011-05-04 |
Actelion Pharmaceuticals Ltd. |
Derivados de 3-heteroaril(amino o amido)-1-(bifenil o feniltiazolil)carbonilpiperidina como inhibidores del receptor de orexina.
|
|
PE20081229A1
(es)
|
2006-12-01 |
2008-08-28 |
Merck & Co Inc |
Antagonistas de receptor de orexina de diazepam sustituido
|
|
AR064561A1
(es)
|
2006-12-28 |
2009-04-08 |
Actelion Pharmaceuticals Ltd |
Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
|
|
CL2008000836A1
(es)
|
2007-03-26 |
2008-11-07 |
Actelion Pharmaceuticals Ltd |
Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
|
|
WO2008143856A1
(en)
|
2007-05-18 |
2008-11-27 |
Merck & Co., Inc. |
Oxo bridged diazepan orexin receptor antagonists
|
|
US8030495B2
(en)
|
2007-05-23 |
2011-10-04 |
Coleman Paul J |
Cyclopropyl pyrrolidine orexin receptor antagonists
|
|
UA99620C2
(en)
|
2007-05-23 |
2012-09-10 |
Мерк Шарп Энд Доме Корп. |
Pyridyl piperidine orexin receptor antagonists
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
MX2009013293A
(es)
|
2007-06-04 |
2010-02-15 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
|
|
CN101730696B
(zh)
*
|
2007-07-03 |
2013-01-09 |
埃科特莱茵药品有限公司 |
3-氮杂-二环[3.3.0]辛烷化合物
|
|
AR067665A1
(es)
|
2007-07-27 |
2009-10-21 |
Actelion Pharmaceuticals Ltd |
Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
|
|
NZ583487A
(en)
*
|
2007-07-27 |
2011-09-30 |
Actelion Pharmaceuticals Ltd |
2-aza-bicyclo[3.3.0]octane derivatives
|
|
EP2207778A2
(en)
*
|
2007-09-24 |
2010-07-21 |
Actelion Pharmaceuticals Ltd. |
Pyrrolidines and piperidines as orexin receptor antagonists
|
|
AU2009215243A1
(en)
|
2008-02-21 |
2009-08-27 |
Actelion Pharmaceuticals Ltd. |
2-aza-bicyclo[2.2.1]heptane derivatives
|
|
CN102015645B
(zh)
*
|
2008-04-30 |
2012-11-14 |
埃科特莱茵药品有限公司 |
哌啶和吡咯烷化合物
|
|
ES2522968T3
(es)
|
2008-06-04 |
2014-11-19 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
CN102083827A
(zh)
*
|
2008-07-07 |
2011-06-01 |
埃科特莱茵药品有限公司 |
作为食欲素受体拮抗剂的噻唑烷化合物
|
|
CA2730603C
(en)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
CA2741125A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
EP2370427A1
(en)
|
2008-12-02 |
2011-10-05 |
Glaxo Group Limited |
N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof
|
|
GB0823467D0
(en)
|
2008-12-23 |
2009-01-28 |
Glaxo Group Ltd |
Novel Compounds
|
|
EA201171293A1
(ru)
|
2009-04-24 |
2012-05-30 |
Глэксо Груп Лимитед |
3-азабицикло[4.1.0]гептаны, применяемые в качестве антагонистов орексина
|
|
US20120149711A1
(en)
|
2009-08-24 |
2012-06-14 |
Glaxo Group Limited |
Piperidine derivatives used as orexin antagonists
|
|
JP2013502447A
(ja)
|
2009-08-24 |
2013-01-24 |
グラクソ グループ リミテッド |
睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体
|
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
WO2012089607A1
(en)
|
2010-12-28 |
2012-07-05 |
Glaxo Group Limited |
Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
|
|
WO2012089606A1
(en)
|
2010-12-28 |
2012-07-05 |
Glaxo Group Limited |
Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
|
|
KR20150075120A
(ko)
|
2011-02-25 |
2015-07-02 |
머크 샤프 앤드 돔 코포레이션 |
항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
|
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
|
US9440982B2
(en)
|
2012-02-07 |
2016-09-13 |
Eolas Therapeutics, Inc. |
Substituted prolines/piperidines as orexin receptor antagonists
|
|
NZ628491A
(en)
|
2012-02-07 |
2016-06-24 |
Eolas Therapeutics Inc |
Substituted prolines / piperidines as orexin receptor antagonists
|
|
CA2873341C
(en)
|
2012-06-04 |
2018-01-02 |
Actelion Pharmaceuticals Ltd |
Benzimidazole-proline derivatives
|
|
EP2880028B1
(en)
|
2012-08-02 |
2020-09-30 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
AU2013328301A1
(en)
|
2012-10-10 |
2015-05-28 |
Actelion Pharmaceuticals Ltd |
Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
|
|
EP2958562B1
(en)
|
2013-02-22 |
2025-09-10 |
Merck Sharp & Dohme LLC |
Antidiabetic bicyclic compounds
|
|
EP2970241A1
(en)
|
2013-03-12 |
2016-01-20 |
Actelion Pharmaceuticals Ltd. |
Azetidine amide derivatives as orexin receptor antagonists
|
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
HK1220696A1
(zh)
|
2013-03-15 |
2017-05-12 |
Bausch Health Ireland Limited |
鸟苷酸环化酶激动剂及其用途
|
|
KR102272746B1
(ko)
|
2013-06-05 |
2021-07-08 |
보슈 헬스 아일랜드 리미티드 |
구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
UA119151C2
(uk)
|
2013-12-03 |
2019-05-10 |
Ідорсія Фармасьютікалз Лтд |
КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
|
|
UA119549C2
(uk)
|
2013-12-03 |
2019-07-10 |
Ідорсія Фармасьютікалз Лтд |
КРИСТАЛІЧНА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ТА ЇЇ ЗАСТОСУВАННЯ ЯК АНТАГОНІСТА ОРЕКСИНОВОГО РЕЦЕПТОРА
|
|
MX366642B
(es)
|
2013-12-04 |
2019-07-17 |
Idorsia Pharmaceuticals Ltd |
Uso de derivados de bencimidazol-prolina.
|
|
ES2901418T3
(es)
|
2014-08-13 |
2022-03-22 |
Eolas Therapeutics Inc |
Difluoropirrolidinas como moduladores del receptor de orexina
|
|
DK3414241T3
(da)
|
2016-02-12 |
2022-08-01 |
Astrazeneca Ab |
Halogensubstituerede piperidiner som orexinreceptormodulatorer
|
|
WO2017194548A1
(en)
|
2016-05-10 |
2017-11-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
|
|
WO2018106518A1
(en)
|
2016-12-06 |
2018-06-14 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
EP3558298A4
(en)
|
2016-12-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
ANTIDIABETIC SPIROCHROMAN COMPOUNDS
|
|
WO2020007964A1
(en)
|
2018-07-05 |
2020-01-09 |
Idorsia Pharmaceuticals Ltd |
2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
|
|
WO2020099511A1
(en)
|
2018-11-14 |
2020-05-22 |
Idorsia Pharmaceuticals Ltd |
Benzimidazole-2-methyl-morpholine derivatives
|
|
EP3972588A4
(en)
|
2019-06-04 |
2023-05-31 |
Hager Biosciences, LLC |
IMIDAZOL DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTS
|
|
WO2023218023A1
(en)
|
2022-05-13 |
2023-11-16 |
Idorsia Pharmaceuticals Ltd |
Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives
|
|
GB202311280D0
(en)
*
|
2023-07-21 |
2023-09-06 |
Bial Portela & Ca Sa |
Orexin receptor antagonists
|
|
GB202311281D0
(en)
*
|
2023-07-21 |
2023-09-06 |
Bial Portela & Ca Sa |
Orexin receptor antagonists
|